Now the question has shifted from "Should we cover GLP-1s?" to "What is actually happening, and what should we do before the next plan year? This comes as Cigna recently removed GLP-1s from coverage for its own employees
Jaime Almandoz, an obesity medicine specialist at the University of Texas Southwestern Medical Center
Add items to your cart, select your preferred payment method and place the order
Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study
[22] [23] By activating GLP-1 receptors, these medications enhance insulin secretion when blood glucose levels are elevated, suppress glucagon release, slow gastric emptying, and promote satiety
We also recently discovered that HFD impairs intestinal NAMPT-mediated NAD + biosynthesis and disrupts the Wnt signaling pathway, GLP-1 production, and whole-body glucose metabolism